Brain Cancer | Specialty

The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Emerging Vaccines in Glioblastoma

December 21st 2016

Glioblastoma: The Potential Role of Immunotherapy

December 21st 2016

Overcoming Challenges in Glioblastoma

December 21st 2016

Glioblastoma: Educating Patients on Tumor-Treating Field Therapy

December 21st 2016

Practical Experience With Optune in Glioblastoma

December 21st 2016

Tumor-Treating Field Therapy in Glioblastoma: Patient Selection

December 21st 2016

New Long-term Data for Tumor-Treating Fields in Glioblastoma

December 21st 2016

Glioblastoma: Impact of Tumor-Treating Field Therapy

December 21st 2016

The Role of Chemoradiotherapy in Glioblastoma

December 21st 2016

Glioblastoma: Guideline Recommendations for Treatment

December 21st 2016

Classification and Prognosis of Glioblastoma

December 21st 2016

Glioblastoma: The Role of Resection

December 21st 2016

Multidisciplinary Care in Glioblastoma

December 21st 2016

What is Glioblastoma?

December 21st 2016

Dr. Reardon on the Need for a New Standard of Care in GBM

December 1st 2016

David A. Reardon, MD, clinical director at the Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the need for a new standard of care in the treatment landscape of glioblastoma multiforme.

Tumor-Treating Fields Make Significant Impact in GBM

December 1st 2016

It’s not often that oncologists get to be the first to utilize cutting-edge technology.

IDO Inhibitors Among Immunotherapy Strategies Under Study in Glioblastoma

November 30th 2016

The concept of using immunotherapies to treat patients with glioblastoma multiforme is gaining ground among researchers who are interested not only in evaluating checkpoint blockade agents that have proved effective in other tumor types but also in exploring novel targets.

Dr. Iavarone on the Role of the ID2 Protein in Brain Cancer

November 22nd 2016

Antonio Iavarone, MD, professor of Pathology and Cell Biology and Neurology, Columbia University, Institute for Cancer Genetics, discusses the role of the ID2 protein in patients with malignant brain tumors.

Phase II Trial Looks to Study Optune's Efficacy in Grade III Recurrent Glioma

November 20th 2016

Researchers are hoping that a proposed phase II study exploring use of the Optune system in patients with recurrent grade III malignant glioma will expand the indications for the tumor treating fields (TTFields) device beyond its current FDA-approved use in recurrent grade IV glioblastoma.

Nivolumab/Radiotherapy Combo Well-Tolerated in Newly Diagnosed GBM

November 20th 2016

Treatment with nivolumab and radiotherapy with or without concurrent temozolomide was well tolerated and showed promising signs of efficacy for patients with newly-diagnosed glioblastoma multiforme.